Canine Immunoglobulin Isotype Selection for Targeted Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in determining which canine immunoglobulin isotypes are active or inactive in mediating immune effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), as this information is crucial for selecting the appropriate isotype for therapeutic antibody development targeting canine diseases like cancer or pain.
Innovation Solution
The identification of specific canine IgG immunoglobulin isotypes, particularly calgG-B and calgG-C, which bind complement, and calgG-A and calgG-D, which do not, allows for the selection of recombinant canine immunoglobulins and fusion proteins that either activate or minimize immune effector functions, enabling targeted therapeutic approaches for cancer or pain treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant canine immunoglobulins are designed to activate immune effector functions (CDC/ADCC) for target destruction, then therapeutic efficacy against cancer or infection is improved, but risk of harmful immune-mediated damage to healthy tissues increases
Solution Approach 1:
The patent applies local quality by selecting specific canine immunoglobulin isotypes (calgG-A or calgG-D) that possess the local property of being unable to activate complement or Fc receptors, thereby confining the therapeutic action to antigen neutralization only without triggering harmful immune effector functions in healthy tissues
Solution Approach 2:
The patent changes the parameter of isotype selection from conventional IgG1/IgG3 (which activate CDC/ADCC) to specific canine isotypes calgG-A or calgG-D (which do not activate these pathways), thereby altering the immune activation profile to achieve therapeutic effect without harmful side effects
2Strength
If the Fc domain is included in recombinant immunoglobulins to enable immune-mediated destruction, then ability to kill target cells is improved, but ability to safely neutralize soluble mediators in sensitive tissues deteriorates
Solution Approach 1:
The patent applies local quality by selecting Fc domains from canine immunoglobulin isotypes calgG-A or calgG-D that possess the local property of inability to bind C1q or activate Fc receptors, thereby enabling the Fc domain to be present without triggering harmful immune effector functions in sensitive tissues
Solution Approach 2:
The patent uses the Fc domain structure from natural canine immunoglobulins calgG-A or calgG-D as a template to construct recombinant immunoglobulins that replicate the safe neutralization profile of natural antibodies while maintaining therapeutic antigen-binding capability
3Strength
If conventional human IgG1 or IgG3 isotypes are used in canine therapeutics, then immune-mediated destruction mechanisms are activated, but specificity for canine immune system responses and safety profile deteriorates
Solution Approach 1:
The patent changes the parameter of species and isotype origin from conventional human IgG1/IgG3 to canine immunoglobulin isotypes calgG-A or calgG-D, thereby adapting the therapeutic antibody to the canine immune system's specific response patterns and safety requirements
Solution Approach 2:
The patent copies the Fc domain sequences from natural canine immunoglobulins calgG-A or calgG-D to create recombinant antibodies that are structurally and functionally compatible with the canine immune system, ensuring appropriate recognition and safety profiles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This distinction enables the development of recombinant canine immunoglobulins that can selectively activate or avoid immune-mediated destruction, improving the efficacy and safety of therapeutic treatments by matching the isotype with the intended therapeutic use, whether for target destruction or neutralization.
Implementation Method 1
the constant region sequence of an antibody can mediate a strong influence on characteristics such as effector functions (ADCC, complement fixing and activation)
Implementation Method 2
Antibodies having different isotypes also differ in terms of their ability to bind to IgG Fc receptors on immune cells
Data Source
AI summary
A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine.